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What’s already known on this topic? 
 There are no large-size studies regarding natural course of pregnancy in cases with congenital 
anomalies.  
 Most studies concern small single center series with limited generalizability. 
 
 
What does this study add? 
 By using the EUROCAT Network, representing a large number of European registries and a wide 
range of anomalies, we were able to perform detailed analyses of the course of pregnancy in 
terms of stillbirth, early or late neonatal mortality for categories of anomalies, by gestational age 
and for a large number of isolated anomalies. 






To provide prognostic information to help parents to reach an informed decision about termination 
or continuation of the pregnancy and to shape peripartum policy based on a large European cohort. 
Method 
Thirteen registries from the European Surveillance of Congenital Anomalies (EUROCAT) network 
contributed data from January 1, 1998 to December 31, 2011. Terminations for fetal anomalies were 
excluded. Chromosomal anomalies, syndromes and isolated anomaly groups were distinguished 
according to EUROCAT guidelines. Perinatal mortality, stillbirths, and early and late neonatal 
mortality rates (NMR)were analyzed by anomaly group and gestational age. 
Results 
Among 73,337 cases, perinatal mortality associated with congenital anomaly was 1.27 per 1,000 
births (95% CI 1.23–1.31). Average stillbirth rate was 2.68%, (range 0–51.2%). Early and late NMR 
were 2.75% (range 0–46.7%) and 0.97% (range 0-17.9%), respectively. Chromosomal anomalies and 
syndromes, and most isolated anomalies, had significant differences regarding timing of fetal demise 
compared to the general population. Chromosomal and central nervous system anomalies had 
higher term stillbirth rates. 
Conclusions 
We found relevant differences between anomalies regarding rates of stillbirth, NMR and timing by 
gestational age. Our data can help parents to decide about their unborn child with a congenital 
anomaly and help inform maternal-fetal medicine specialists regarding peripartum management. 
INTRODUCTION 1 
Prenatal ultrasound screening for congenital anomalies (CA) has been implemented in many 2 
countries in Europe and around the world.(1-4) It has provided parents with the option of informed 3 
choice for delivery in a neonatal center or termination of the pregnancy in the case of a serious fetal 4 
anomaly (TOPFA) in countries where this option is available.(5,6) Clinical geneticists and obstetricians 5 
play an important role in this decision by providing accurate information regarding the prognosis of 6 
the fetus during the counseling process. However, despite modern ultrasound technology not all 7 
congenital anomalies can be detected early, and situations remain where an anomaly is discovered 8 
beyond the time window during which termination is legally allowed or at birth or soon after birth. In 9 
such cases, or in cases where the decision was made to continue the pregnancy despite the presence 10 
of an anomaly, it is important to have information about the probability of fetal demise associated 11 
with a specific anomaly. This will help parents and health care professionals to reach a decision in 12 
time, taking into account the prognosis of the newborn after birth and the probability of stillbirth 13 
during the remainder of the pregnancy. In addition, prognostic information may help to determine 14 
peripartum policy, e.g. in terms of abstaining from lifesaving interventions in case of an anomaly with 15 
a very poor prognosis, or to reassure parents in case of an anomaly with a good prognosis. 16 
Studies have shown that the presence of CA is associated with an increased risk of stillbirth.(7,8) 17 
Overall, CA are found in up to 20% of stillbirths, with or without chromosomal anomalies.(9-11) In a 18 
large cohort of stillbirth cases, classification of the cause of death revealed that 4.7% of stillbirths in 19 
normally formed fetuses has been attributed to severe or lethal CA.(12) However, recent data on 20 
stillbirth risk and pregnancy outcomes for specific anomalies are scarce or fragmented and do not 21 
allow comparative evaluation of fetal survival in pregnancies complicated by CA.(13-18) 22 
We have used detailed data from national and regional registries participating in the EUROCAT 23 
network to assess the course of pregnancies complicated by CA in cases where TOPFA is not 24 
performed. We determined the prevalence of stillbirth and early and late neonatal mortality by 25 
gestational age, specifically investigating the most common chromosomal anomalies (i.e. trisomy 21, 26 
trisomy 18 and trisomy 13), other syndromes such as monogenic anomalies and skeletal dysplasias, 27 
and specific isolated anomalies according to the EUROCAT classification.(19) Our research questions 28 
were: 29 
 In pregnancies complicated by CA, what is the probability of stillbirth and early and late neonatal 30 
mortality for common chromosomal anomalies, other syndromes and specific isolated CA?  31 
 At what gestational or neonatal age does mortality occur in these cases? 32 
 33 
MATERIALS 34 
We used data provided by thirteen EUROCAT registries (http://www.eurocat-network.eu) for the 35 
years 1998 – 2011 or for part of this period (see Table 1 for details). Only registries that had 36 
information about the date of death for more than 80% of cases were selected to participate in the 37 
study. Anomalies had to be within the ICD9 range 740-759 or the ICD10 Q chapter (International 38 
Classification of Diseases, 9th revision (ICD-9) and 10th revision (ICD-10), www.who.int) and only major 39 
anomalies according to EUROCAT coding were included. (20) Perinatal mortality was defined as 40 
either stillbirth or early neonatal mortality, with stillbirth defined as at least 20 weeks of completed 41 
gestation and no signs of life at birth according to EUROCAT definitions and early neonatal mortality 42 
defined as death within seven completed days after birth in accordance with WHO definitions.(21) 43 
Late neonatal mortality was defined as death between 7 and 27 days after live birth. EUROCAT data 44 
on the pregnancy outcome (i.e. TOPFA, stillbirth, survival more than or less than 1 week after live 45 
birth) were used to determine perinatal and early neonatal mortality. Late neonatal mortality was 46 
determined using the date of death, which was recorded in cases of known mortality beyond one 47 
week after birth up to 27 days. For the current analysis, we examined the course of pregnancies with 48 
a known pregnancy outcome. TOPFA cases were excluded. We divided the cases into three mutually 49 
exclusive categories according to EUROCAT guidelines.(19) The first category consisted of trisomies 50 
and other chromosomal anomalies. The second category consisted of syndromes: genetic syndromes 51 
or microdeletions, monogenic anomalies, sequences, teratogenic anomalies, skeletal dysplasias and 52 
other unclassified syndromes. The third category consisted of isolated non-syndromal anomalies 53 
defined as the absence of chromosomal anomalies, multiple anomalies and syndromes. A case was 54 
classified as a multiple anomaly when two or more unrelated, major structural malformations were 55 
present that could not be explained by an underlying syndrome or sequence. Isolated anomalies 56 
were identified using EUROCAT’s multiple malformation algorithm19 and included the following main 57 
groups of anomalies: central nervous system, eye, ear, face and neck; congenital heart defects (CHD) 58 
with severe CHD specified separately; respiratory system; digestive system; orofacial clefts; 59 
abdominal wall defects; urinary tract; genital tract; limb defects and other anomalies. For all main 60 
groups, the most prevalent CA were specified. In addition, two distinct entities, neural tube defects 61 
and severe congenital heart defects, were also tabulated. Gestational age at birth was categorized 62 
according to the WHO criteria (www.who.int) into extreme preterm (less than 28 weeks), very 63 
preterm (from 28 to less than 32 weeks), moderate-late preterm (from 32 to less than 37 weeks) and 64 
term (37 weeks or longer). 65 
The prevalence of CA and the 95% confidence intervals were calculated using counts of CA and total 66 
births provided by the registries. The distribution of mortality and timing of mortality were examined 67 
using chi-square tests, comparing cases with the respective CA versus all other cases. A p-value of 68 
less than 0.05 was considered statistically significant. All analyses were performed using SPSS version 69 
23 (IBM Corp, Armonk, USA).  70 
Patient involvement, ethics and originality 71 
Patients were not involved in the design of this study. The data used in this study are registry-based 72 
and anonymized; no additional consent for this study was required. Results of EUROCAT studies are 73 
disseminated through their website which is freely accessible. This work is original and has not been 74 
published elsewhere.   75 
RESULTS 76 
Thirteen registries provided data for a total of 84,795 cases of CA over the 14-year study period 77 
(Table 1). The total number of births was more than 3 million, resulting in an overall prevalence of CA 78 
of 27.3 per 1000 births, ranging between registries from 19.1 to 39.3 per 1000 births. The pregnancy 79 
outcome was known for 99.4% of pregnancies (408 were unknown). Of the pregnancies with known 80 
outcome (n=84, 387), 2.33% (n=1968, range 0.91% – 6.6%) concerned stillbirths, 2.37% (n=2015, 81 
range 0.68% – 7.6%) early and 0.84% (n=710, range 0.09% – 2.26%) late neonatal mortality. In 13.1% 82 
of cases (n=11,050), the pregnancy ended in a TOPFA. 83 
Table 1 to be placed here. 84 
The first column in table 2 shows the total number and percentage of anomalies by subgroup for the 85 
73,337 cases with known mortality outcome (after exclusion of TOPFA). For the isolated anomalies 86 
(n=44,991), the second column shows the total number and percentage of all isolated anomalies for 87 
the sake of comparison to the subgroups in the first column. No relevant over- or 88 
underrepresentation of anomaly subgroups in the isolated cohort was apparent, except for bilateral 89 
renal agenesis (0.3% versus 0.01%). The time of discovery of the anomaly was recorded for 99.6% of 90 
all cases. Apart from the main categories ‘At birth ’ (34.8%) and ‘Prenatal’ (20.2%), the largest 91 
categories were ‘Within 1 week’ (11.4%) and ‘1-12 months’ (11.5%). In 9.8% of cases, time of 92 
discovery was recorded as ‘Unknown’. Discovery within 4 weeks occurred in 4.4% and discovery 93 
more than one year after birth occurred in 3.8%. Postnatal diagnosis but with unknown age occurred 94 
in 3.7% of cases (data not shown). 95 
Table 2 to be placed here. 96 
Among the chromosomal anomalies, representing 8.6% of all CA, trisomy 21 was by far the most 97 
prevalent. The subgroup “other syndromes” represented 30.1% of anomalies and consisted mainly of 98 
unclassified syndromes (23.2%). The most common isolated CA were CHD (severe congenital heart 99 
defects, ventricular septal defect without severe CHD, and atrial septal defect without severe CHD), 100 
limb defects (hip dislocation/dysplasia), urinary tract anomalies (congenital hydronephrosis) and 101 
hypospadias.  102 
Table 2 also presents the distribution of stillbirth, early and late neonatal mortality cases for all CA. 103 
Overall, stillbirth and early neonatal mortality rates were comparable, while late neonatal mortality 104 
occurred less frequently. Figure 1 shows clear differences in causes of mortality among the main 105 
categories of anomalies. Stillbirth was most prevalent in chromosomal anomalies while early and late 106 
neonatal mortality were more prevalent in chromosomal anomalies and in syndromes. 107 
The highest rates of stillbirth and early neonatal mortality were observed for isolated central nervous 108 
system anomalies, respiratory system anomalies, diaphragmatic hernia and abdominal wall defects, 109 
while the lowest rates were observed for isolated urinary tract anomalies and limb defects. 110 
Significant differences compared to overall mortality patterns were observed for most anomaly 111 
groups, with the exception of ear, face, and neck anomalies; Tetralogy of Fallot; aortic valve 112 
atresia/stenosis; choanal atresia; renal dysplasia and limb reduction. 113 
Table 3 shows stillbirth by gestational age. Thirteen cases were excluded from this analysis because 114 
the gestational age was missing. The overall distribution according to gestational age showed that 115 
stillbirth predominately occurred at extreme preterm gestational age (37.9%) and was less frequent 116 
between 28 and 32 weeks of gestation (16.1%), while 21.5% of stillbirths occurred at term. A 117 
summary of the distribution of stillbirth by gestational age is shown in Figure 2. 118 
Table 3 to be placed here. 119 
Extreme preterm stillbirth occurred in 0% to 68.2% of stillbirths among specific anomaly subgroups. 120 
The highest prevalence concerned 15 of 22 cases of clubfoot/talipes equinovarus, which is less than 121 
1% of total clubfoot/talipes cases (n=2,018). Very preterm stillbirth occurred in 0% to 46.2% (renal 122 
dysplasia). Patterns significantly deviating from the overall distribution were observed for trisomies 123 
21 and 18, suggesting higher prevalences of stillbirth at higher gestational ages (P<0.001). For neural 124 
tube defects and anencephaly in particular, a similar pattern was observed. Stillbirth occurred 125 
predominantly at extreme preterm gestation (P<0.001) in the categories other chromosomal 126 
anomalies and other syndromes. For many subgroups of anomalies, the numbers were too small to 127 
allow reliable statistical evaluation.  128 
Table 4 shows early and late neonatal mortality rates by type of CA. Overall, early and late neonatal 129 
mortality occurred mainly in children born at term. This could be expected due to the majority of 130 
births occurring at term, but data on total births were not available by gestational age, so this could 131 
not be verified. The highest early neonatal mortality rates were observed for central nervous system 132 
(CNS) anomalies (24.1%) and CHD. These anomalies also showed significantly different distributions, 133 
with less predominance at term for CNS anomalies (43.6% versus 54.6% overall, P<0.05) but stronger 134 
predominance at term for CHD (76.2% versus 54.6% overall, P<0.005). Some other anomalies such as 135 
chromosomal anomalies, genetic syndromes, respiratory and digestive anomalies, urinary tract 136 
anomalies and some limb defects also differed significantly from the general distribution. The small 137 
number of cases showing late neonatal mortality did not allow for meaningful analysis for many 138 
subgroups of anomalies. In general, most of the late neonatal mortality occurred in pregnancies at or 139 
near term. Significant differences indicating a stronger predominance of mortality at term were 140 
observed for CHD and severe cases in particular (P<0.005), as well as for non-chromosomal 141 
syndromes (P<0.001), digestive (P<0.05) and urinary anomalies (P<0.001). 142 
Table 4 to be placed here. 143 
  144 
DISCUSSION 145 
 146 
This study provides accurate information about the prognosis for counseling parents faced with the 147 
decision of whether to continue their pregnancy following antenatal diagnosis of a congenital 148 
anomaly or in situations where an anomaly is discovered beyond the time window during which 149 
termination is legally allowed or in case of discovery at or soon after birth. Using multicenter data 150 
from the EUROCAT network, we found distinct and clinically relevant differences between anomalies 151 
with respect to the occurrence of stillbirth and early and late neonatal mortality, and also with 152 
respect to the timing of these events by categorized gestational age. 153 
 154 
Strengths 155 
We were able to use a large database of CA cases from the EUROCAT network, representing a large 156 
number of European registries and a wide range of anomalies. We selected registries with the 157 
highest degree of completeness of mortality data and excluded pregnancies that resulted in a TOPFA. 158 
The participating registries showed a wide geographic distribution across Europe and a mix of 159 
practice and legal status regarding TOPFA. Coding of anomalies was performed according to 160 
EUROCAT guidelines, improving the quality and standardization of the data.(22,23) 161 
 162 
Limitations 163 
Unfortunately, EUROCAT data do not include information regarding type of delivery, i.e. induced or 164 
spontaneous, or about active or non-active management during delivery. The latter may influence 165 
whether a baby is eventually registered as stillbirth or as an early neonatal death. Also, we cannot 166 
distinguish intrapartum death from prepartum death, which are both coded as stillbirth. Of the 167 
pregnancies that we analyzed, about 50% of mortality occurred in the first or second day of life, and 168 
about 50% concerned stillbirths. Participation of more registries would have been preferable but 169 
might have impacted the completeness and quality of the data. Finally, EUROCAT contains only 170 
anomaly cases; no data on pregnancies without anomalies is available. Therefore, we could only 171 
calculate relative risk of mortality compared to all other anomalies, not absolute risk. 172 
 173 
Interpretation 174 
The participating registries differ with respect to some important aspects of our study, most 175 
obviously regarding the availability and practice of TOPFA. Other factors that could affect the rate of 176 
perinatal mortality, including differences in perinatal clinical practice between registry regions (e.g. 177 
abstinence from active intervention during labor or immediately post-partum) are not captured in 178 
our data. Overall, 20.2% of the anomalies in our database were discovered prenatally, and 34.8% at 179 
birth. Thus, although policy differences could have determined whether the outcome was coded as 180 
stillbirth or early or late neonatal mortality, this would not have affected the majority of cases. On 181 
the other hand, about 50% of mortality occurred on the first or second day after birth. 182 
The prevalence of perinatal mortality in our data (1.27 per 1000 births) is representative of the 183 
European population (European Perinatal Health Report 2010, www.europeristat.com). The causes 184 
of the differences in overall perinatal mortality figures between countries have been debated 185 
(European Perinatal Health Report 2010, www.europeristat.com). Our data suggest that 2-3 CA cases 186 
per 1000 births contribute to overall perinatal mortality in countries with high perinatal mortality 187 
due to CA and low TOPFA. In countries with low perinatal mortality due to CA and high TOPFA, the 188 
contribution of CA to overall perinatal mortality would be expected to be less than 1%. 189 
Our data show that only a few anomaly types are lethal in the majority of cases. These include 190 
trisomy 18 (77.8%), trisomy 13 (75.5%) and anencephaly (99.6%). On the other hand, some 191 
anomalies in our data are associated with a relatively good prognosis, such as monogenic anomalies 192 
and CHD. Some of the large subgroups of anomalies, such as the trisomies, CNS anomalies, and CHD, 193 
have previously been studied individually with respect to mortality outcomes.(7,13,17,24-28) 194 
However, these studies generally focused on either stillbirth or neonatal mortality, not both.  195 
For trisomies, our study is one of the largest series focused on survival published to date. Previous 196 
papers have reported stillbirth rates of 5.4% - 6.2% of all pregnancies for trisomy 21, equivalent to 197 
7% - 8% if TOPFA is taken into account(17,29), and 49% - 72% in cases of trisomy 13 and 18, 198 
respectively.(30,31) Smaller case series have reported even higher figures.(27) In a relatively small 199 
series, early neonatal mortality in trisomy 13 and 18 was between 54% and 64%, higher than our 200 
results.(30) Few previous reports specified stillbirth and neonatal mortality in relation to gestational 201 
age. Frey and colleagues reported on stillbirth by gestational age in a population of selected major 202 
anomalies in the USA but did not separate their cases by type of anomaly.(7) They showed that the 203 
overall occurrence of stillbirth was equal before and after 32 weeks. Our data for chromosomal 204 
anomalies, including both trisomies and chromosomal anomalies in general, show that stillbirths 205 
occurred more often before 28 weeks and after 32 weeks of gestation than in the intermediate stage 206 
of 28 - 32 weeks.  207 
With respect to isolated anomalies, CHD are widely studied, with some large series based on 208 
EUROCAT data(32,33) or data from other registries.(25,26) Reported stillbirth rates ranged between 209 
1% and 3%, with perinatal and neonatal mortality of 3% and 6%, respectively. These rates are slightly 210 
higher than in our rates, which may be explained by the fact that we only included isolated CHD, 211 
which may represent relatively uncomplicated cases.  212 
Among isolated CNS anomalies, only relatively small series on neural tube defects have been 213 
published to date.(34-36) Stillbirth (4-19%) and neonatal mortality rates (7-20%) reported by these 214 
studies are variable, partly due to small numbers of cases, but are in the same range as those found 215 
in our results.  216 
 217 
Generalizability 218 
Our data were extracted from the EUROCAT registry based on the voluntary participation of registry 219 
leaders and availability of survival data. Overall, EUROCAT surveys over 1.7 million births per year, 220 
covering approximately 29% of the European birth population and offering high-quality data(22). Our 221 
data are therefore not expected to be strongly biased by selection and are the best possible source 222 
to study questions related to CA on a large scale. 223 
 224 
Conclusion 225 
Our data show that the prognosis of pregnancies differs significantly according to CA. For most types 226 
of anomalies, we had much larger numbers of cases than have been reported in the literature so far. 227 
Our results provide more support for the decision making process of parents and healthcare 228 
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Figure 1: Causes of mortality among main categories of congenital anomalies. Note that the Y-axis 






























Figure 2: Distribution of stillbirth by gestational age. Extreme PT:  extreme preterm; very PT:  very 


































Table 1. Total number of births, number of congenital anomalies (CA), CA prevalence, terminations of pregnancy for fetal anomaly (TOPFA), stillbirth, early 
and late neonatal mortality and perinatal mortality associated with CA per EUROCAT registry, 1998-2011* 










Perinatal and neonatal mortality 
   (n) per 1,000 births 
(95% CI) 
 prevalence 














Denmark, Odense 74,398 2,146 28.8 (27.6-30.0) 353 (16.5) 1.25 (1.00-1.50) 50 (2.3) 43 (2.0) 10 (0.47) 
Italy, Tuscany 400,976 8,678 21.6 (21.2-22.1) 1605 (18.5) 0.35 (0.29-0.41) 81 (0.93) 61 (0.68) 39 (0.45) 
Ireland, Dublin 336,462 6,472 19.2 (18.8-19.7) 0 (0) 2.43 (2.26-2.59) 408 (6.6) 416 (6.6) 96 (1.48) 
Northern Netherlands 265,933 7,068 26.6 (26.0-27.2) 631 (8.9) 1.49 (1.34-1.64) 177 (2.5) 219 (3.1) 77 (1.09) 
Switzerland, Vaud 104,594 4,110 39.3 (38.1-40.5) 783 (19.1) 0.91 (0.73-1.09) 46 (1.1) 49 (1.2) 16 (0.39) 
Germany, Saxony Anhalt 231,698 7,567 32.7 (32.0-33.4) 829 (11.0) 0.86 (0.74-0.98) 127 (1.7) 73 (0.97) 7 (0.09) 
Austria, Styria 146,395 4,771 32.6 (31.8-33.6) 525 (10.9) 0.84 (0.69-0.99) 61 (1.3) 64 (1.4) 26 (0.54) 
Ireland, Cork and Kerry 126,380 3,325 26.3 (25.4-27.2) 26 (0.79) 2.47 (2.20-2.74) 131 (4.0) 182 (5.5) 49 (1.47) 
UK, Wales 466,301 18,249 39.1 (38.6-39.7) 2493 (13.6) 1.31 (1.20-1.41) 344 (1.9) 275 (1.4) 99 (0.54) 
Ukraine
#
 208,772 5,085 24.4 (23.7-25.0) 664 (13.1) 1.81 (1.63-1.99) 168 (3.3) 208 (4.2) 115 (2.26) 
UK, Northern England
$
 382,900 9,351 24.4 (23.9-24.9) 1982 (21.2) 1.18 (1.07-1.29) 266 (2.8) 185 (2.0) 76 (0.81) 
South East Ireland 95,837 1,829 19.1 (18.2-20.0) 3 (0.17) 1.96 (1.68-2.24) 53 (2.9) 137 (7.6) 39 (2.13) 
Spain, Valencia region
^
 267,408 6,144 23.0 (22.4-23.5) 1156 (18.8) 0.59 (0.50-0.69) 56 (0.91) 103 (1.7) 61 (0.99) 
Total 3,108,054 84,795** 27.3 (27.1-27.5) 11,050 (13.1) 1.27 (1.23-1.31) 1,968 (2.33) 2,015 (2.37) 710 (0.84) 
 
CA: congenital anomaly; TOPFA: termination of pregnancy for fetal anomaly 




: 2000-2011; ^: 2007-2011 
** Including 408 cases with unknown pregnancy outcome  
Table 2. Perinatal and neonatal mortality for chromosomal anomalies, syndromes and isolated anomalies 
Anomaly group Total number 
excluding TOPFA 
(n, % of total) 
Number 
isolated 
(n, % of total) 
Stillbirth 
 
(n,% of group) 
Early neonatal 
mortality 
(n, % of group) 
Late neonatal 
mortality 
(n, % of group) 
All anomalies 73,337 (100) - 1,968 (2.68) 2015 (2.75) 710 (0.97) 
Chromosomal anomalies 6,286 (8.6) - 604 (9.6) 349 (5.6) 131 (2.1) 
 Trisomy 21 3,684 (5.0) - 182 (4.9) 51 (1.4) 26 (0.7)
#
 
 Trisomy 18 482 (0.7) - 177 (36.7) 149 (30.9) 49 (10.2)
#
 
 Trisomy 13 212 (0.3) - 47 (22.2) 85 (40.1) 28 (13.2)
#
 
 Other 1,908 (2.6) - 198 (10.4) 64 (3.4) 28 (1.5)
#
 
Syndromes 22,060 (30.1) - 753 (3.4) 945 (4.3) 303 (1.4)
#
 
 Genetic syndromes/microdeletions 2,704 (3.7) - 54 (2.0) 67 (2.5) 50 (1.8) 
 Monogenic anomalies 897 (1.2) - 15 (1.7) 26 (2.9) 7 (0.8) 
 Sequences 638 (0.9) - 66 (10.3) 113 (17.4) 5 (0.8) 
 Teratogenic anomalies 425 (0.6) - 19 (4.5) 6 (1.4) 6 (1.4) 
 Skeletal dysplasias 348 (0.5) - 22 (6.3) 47 (13.5) 3 (0.9) 
 Other 17,048 (23.2) - 577 (3.4) 688 (4.0) 232 (1.4) 
Isolated anomalies 44,991 (61.3) 44,991 (100) 611 (1.35) 721 (1.60) 276 (0.61) 
CNS 5,288 (7.2) 2,303 (5.1) 236 (10.2) 172 (7.5) 32 (1.4)
#
 
 Neural tube defects 1,234 (1.7) 747 (1.7) 160 (21.4) 132 (17.7) 12 (1.6)
#
 
  Spina bifida 782 (1.1) 435 (1.0) 26 (6.0) 15 (3.4) 6 (1.4)
#
 
  Anencephaly 287 (0.4) 240 (0.5) 123 (51.2) 112 (46.7) 4 (1.7)
#
 
Anomaly group Total number 
excluding TOPFA 
(n, % of total) 
Number 
isolated 
(n, % of total) 
Stillbirth 
 
(n,% of group) 
Early neonatal 
mortality 
(n, % of group) 
Late neonatal 
mortality 
(n, % of group) 
  Encephalocele 165 (0.2) 72 (0.2) 11 (15.3) 5 (6.9) 2 (2.8)
#
 
 Hydrocephaly 1,063 (1.4) 435 (1.0) 37 (8.5) 16 (3.7) 5 (1.1)
#
 
 Arhinencephaly/holoprosencephaly 175 (0.2) 43 (0.1) 5 (11.6) 8 (18.6) 2 (4.7)
#
 
Eye anomalies 2180 (3.0) 913 (2.0) 2 (0.2) 3 (0.3) 1 (0.1)
#
 
 Congenital cataract 630 (0.9) 392 (0.9) 0 0 0
##
 
Ear, face, neck 1,082 (1.5) 221 (0.5) 3 (1.4) 1 (0.5) 0 
 Anotia 67 (0.1) 29 (0.1) 1 (3.4) 1 (3.4) 0 
Congenital heart defects 26,835 (36.6) 14,932 (33.2) 101 (0.7) 235 (1.6) 168 (1.1)
#
 
 Severe CHD** 6,446 (8.8) 2,768 (6.2) 50 (1.8) 170 (6.1) 132 (4.8)
#
 
  Transposition great vessels 1,059 (1.4) 563 (1.3) 2 (0.4) 35 (6.2) 25 (4.4)
#
 
  Coarctation aorta 1,405 (1.9) 526 (1.2) 6 (1.1) 6 (1.1) 10 (1.9)
##
 
  Fallot’s tetralogy 960 (1.3) 475 (1.0) 8 (1.7) 8 (1.7) 2 (0.4) 
  Hypoplastic left/right heart 640 (0.8) 352 (0.8) 17 (4.8) 92 (26.1) 63 (17.9)
#
 
  Single ventricle 164 (0.2) 59 (0.1) 5 (8.5) 7 (11.9) 1 (1.7)
#
 
  Common arterial truncus 194 (0.3) 72 (0.2) 3 (4.2) 8 (11.1) 9 (12.5)
#
 
  Atrioventricular septal defect 1,259 (1.7) 243 (0.5) 8 (3.3) 3 (1.2) 8 (3.3)
#
 
  Tricuspid atresia/stenosis 202 (0.3) 46 (0.1) 1 (2.2) 1 (2.2) 2 (4.3)^ 
  Ebstein’s anomaly 152 (0.2) 52 (0.1) 0 0 5 (9.6)
#
 
  Aortic valve atresia/stenosis 586 (0.8) 299 (0.7) 1 (0.3) 5 (1.7) 3 (1.0) 
  Pulmonary valve atresia 295 (0.4) 73 (0.2) 0 1 (1.4) 4 (5.5)
#
 
Anomaly group Total number 
excluding TOPFA 
(n, % of total) 
Number 
isolated 
(n, % of total) 
Stillbirth 
 
(n,% of group) 
Early neonatal 
mortality 
(n, % of group) 
Late neonatal 
mortality 
(n, % of group) 
  Total anomalous pulmonary 
venous return 
231 (0.3) 109 (0.2) 0 6 (5.5) 7 (6.4)
#
 
 VSD (no severe CHD) 9,268 (12.6) 6,882 (15.3) 15 (0.22) 15 (0.22) 11 (0.16)
#
 
 ASD (no severe CHD) 4,512 (6.2) 1,963 (4.4) 10 (0.5) 1-4 (0.2) 6 (0.3) 
 VSD + ASD (no severe CHD) 1,724 (2.4) 245 (0.5) 0 1 (0.4) 1 (0.4) 
 Pulmonary valve stenosis (no 
severe CHD)*** 
1,708 (2.3) 976 (2.2) 1 (0.1) 3 (0.3) 1 (0.1)
#
 
Respiratory 1,834 (2.5) 664 (1.5) 29 (4.4) 51 (7.7) 6 (0.9)
#
 
 Choanal atresia 300 (0.4) 103 (0.2) 0 0 0 
Digestive 5,620 (7.7) 2,823 (6.3) 40 (1.4) 129 (4.6) 36 (1.3)
#
 
 Diaphragmatic hernia 758 (1.0) 443 (1.0) 15 (3.4) 98 (22.1) 12 (2.7)
#
 
Orofacial clefts 4,576 (6.2) 2,925 (6.5) 29 (1.0) 16 (0.5) 0
#
 
 Cleft lip with or without cleft palate 2,622 (3.6) 1,919 (4.3) 21 (1.1) 10 (0.5) 0
#
 
Abdominal wall defects 1,375 (1.9) 828 (1.8) 47 (5.7) 24 (2.9) 11 (1.3)
#
 
 Gastroschisis 830 (1.1) 653 (1.5) 37 (5.7) 12 (1.8) 10 (1.5)
#
 
 Omphalocele 493 (0.7) 164 (0.4) 9 (5.5) 10 (6.1) 1 (0.6)
#
 
Urinary 9,781 (13.3) 5,111 (11.4) 61 (1.2) 60 (1.2) 14 (0.3)
#
 
 Bilateral renal agenesis 213 (0.3) 4 (0.01) 0 1 (25.0) 0
##
 
 Renal dysplasia 1254 (1.7) 705 (1.6) 13 (1.8) 16 (2.3) 4 (0.6) 
 Congenital hydronephrosis 3,906 (5.3) 2,050 (4.6) 11 (0.5) 10 (0.5) 0
#
 
Genital 6,513 (8.9) 4,577 (10.2) 2 (0.04) 8 (0.2) 0
#
 
Anomaly group Total number 
excluding TOPFA 
(n, % of total) 
Number 
isolated 
(n, % of total) 
Stillbirth 
 
(n,% of group) 
Early neonatal 
mortality 
(n, % of group) 
Late neonatal 
mortality 
(n, % of group) 
 Hypospadias 5,466 (7.5) 4,126 (9.2) 1 (0.02) 2 (0.04) 0 (0)
#
 
Limb defects 13,565 (18.5) 8,682 (19.3) 41 (0.5) 20 (0.2) 5 (0.04)
#
 
 Limb reduction 1,426 (1.9) 497 (1.1) 9 (1.8) 5 (1.0) 0 
 Clubfoot/talipes equinovarus 2,917 (4.0) 2,018 (4.5) 22 (1.1) 7 (0.3) 3 (0.1)
#
 
 Hip dislocation/dysplasia 4,006 (5.5) 3,077 (6.8) 0 0 1 (0.03)
#
 
 Polydactyly 2,468 (3.4) 1,663 (3.7) 5 (0.3) 4 (0.24) 1 (0.06)
#
 
 Syndactyly 1,443 (2.0) 659 (1.5) 1 (0.1) 1 (0.1) 0 (0)
#
 




TOPFA: termination of pregnancy for fetal anomaly; ASD: atrial septal defect; VSD: ventricular septal defect; CHD: congenital heart disease; CNS: central nervous system 
* Overlap of main group less than 1% 
** More than one component present in 627 cases 
*** Overlap with VSD or ASD without severe CHD in 555 (32.5%) of total cases and 109 isolated cases (11.2%) 
#
 P< 0.001; 
##
 P< 0.01; 
^
 P<0.05 for comparison to overall mortality in all other CA. 
 
  
Table 3. Stillbirth by gestational age for chromosomal anomalies, syndromes, and isolated anomalies 
Anomaly group All stillbirth 
 
 




(n, % of group) 
Very preterm 
 
28 - <32 wks 
(n, % of group) 
Moderate-late 
 preterm  
32 - <37 wks 




(n, % of group) 
All anomalies 1,955 (100) 740 (37.9) 315 (16.1) 480 (24.6) 420 (21.5) 
Chromosomal anomalies 595 (30.4) 224 (37.6) 88 (14.8) 135 (22.7) 148 (24.9) 
 Trisomy 21 179 (9.2) 52 (29.1) 19 (10.6) 56 (31.3) 52 (29.1)
##
 
 Trisomy 18 176 (9.0) 35 (19.9) 39 (22.2) 39 (22.2) 63 (35.8)
##
 
 Trisomy 13 45 (2.3) 21 (46.7) 7 (15.6) 11 (24.4) 6 (13.3) 
 Other 195 (10.0) 116 (59.5) 23 (11.8) 29 (14.9) 27 (13.8)
##
 
Syndromes 749 (38.3) 299 (39.9) 134 (17.9) 188 (25.1) 128 (17.1)
##
 
 Genetic syndromes/microdeletions 53 (3.9) 25 (47.2) 9 (17.0) 13 (24.5) 6 (11.3) 
 Monogenic anomalies 15 (0.2) 5 (33.3) 4 (26.7) 5 (33.3) 1 (6.7) 
 Sequences 65 (4.8) 36 (55.4) 5 (7.7) 16 (24.6) 8 (12.3) 
 Teratogenic anomalies 19 (1.4) 6 (31.6) 6 (31.6) 4 (21.1) 3 (15.8) 
 Skeletal dysplasias 22 (1.6)  2 (9.1) 4 (18.2) 12 (54.5) 4 (18.2) 
 Other 575 (42.3) 225 (39.1) 106 (18.4) 138 (24.0) 106 (18.4) 
Isolated anomalies 611 (31.3) 221 (35.9)  93 (15.1) 157 (25.5) 145 (23.5) 
CNS 236 (38.6) 60 (25.4) 31 (13.1) 76 (32.2) 69 (29.2)
##
 
 Neural tube defects 160 (26.2) 29 (18.1) 22 (13.8) 53 (33.1) 56 (35.0)
##
 
  Spina bifida 26 (4.3) 10 (38.5) 1 (3.8) 5 (19.2) 10 (38.5) 
  Anencephaly 123 (20.1) 16 (13.0) 21 (17.1) 45 (36.6) 41 (33.3)
##
 
Anomaly group All stillbirth 
 
 




(n, % of group) 
Very preterm 
 
28 - <32 wks 
(n, % of group) 
Moderate-late 
 preterm  
32 - <37 wks 




(n, % of group) 
  Encephalocele 11 (1.8) 3 (27.3) 0 3 (27.3) 5 (45.6) 
 Hydrocephaly 37 (6.1) 14 (37.8) 3 (8.1) 11 (29.7) 9 (24.3) 
 Arhinencephaly/holoprosencephaly 5 (0.8) 0 1 (20.0) 2 (40.0) 2 (40.0) 
Eye anomalies 2 (0.3) 0 0 1 (50.0) 1 (50.0) 
 Congenital cataract 0 - - - - 
Ear, face, neck 3 (0.5) 0 2 (66.7) 1 (33.3) 0 
 Anotia 1 (0.2) 0 0 1 (100.0) 0 
Congenital heart defects 101 (16.5) 40 (39.6) 21 (20.8) 23 (22.8) 17 (16.8) 
 Severe CHD* 50 (8.2) 17 (34.0) 10 (20.0) 13 (26.0) 10 (20.0) 
  Transposition great vessels 2 (0.3) 0 1 (50.0) 1 (50.0) 0 
  Coarctation aorta 6 (1.0) 3 (50.0) 2 (33.3) 1 (16.7) 0 
  Fallot’s tetralogy 8 (1.3) 4 (50.0) 3 (37.5) 1 (12.5) 0 
  Hypoplastic left/right heart 17 (2.8) 6 (35.3) 2 (11.8) 5 (29.4) 4 (23.5) 
  Single ventricle 5 (0.8) 2 (40.0) 1 (20.0) 1 (20.0) 1 (20.0) 
  Common arterial truncus 3 (0.5) 0 1 (33.3) 0 2 (66.7) 
  Atrioventricular septal defect 8 (1.3) 2 (25.0) 0 4 (50.0) 2 (25.0) 
  Tricuspid atresia/stenosis 1 (0.2) 0 0 0 1 (100.0) 
  Ebstein’s anomaly 0 - - - - 
  Aortic valve atresia/stenosis 1 (0.2) 0 0 1 (100.0) 0 
Anomaly group All stillbirth 
 
 




(n, % of group) 
Very preterm 
 
28 - <32 wks 
(n, % of group) 
Moderate-late 
 preterm  
32 - <37 wks 




(n, % of group) 
  Pulmonary valve atresia 0 - - - - 
  Total anomalous pulmonary 
venous return 
0 - - - - 
 VSD (no severe CHD) 15 (2.5) 10 (66.7) 4 (26.7) 1 (6.7) 0
#
 
 ASD (no severe CHD) 10 (1.6) 2 (20.0) 0 3 (30.0) 5 (50.0) 
 VSD + ASD (no severe CHD) 0 - - - - 
 Pulmonary valve stenosis (no severe 
CHD) 
1 (0.2) 0 1 (100.0) 0 0 
Respiratory 29 (4.7) 13 (44.8) 4 (13.8) 6 (20.7) 6 (20.7) 
 Choanal atresia 0 - - - - 
Digestive 40 (6.5) 10 (25.0) 4 (10.0) 13 (32.5) 13 (32.5) 
 Diaphragmatic hernia 15 (2.5) 3 (20.0) 0 5 (33.3) 7 (46.7) 
Orofacial clefts 29 (4.7) 15 (51.7) 4 (13.8) 5 (17.2) 5  (17.2) 
 Cleft lip with/without cleft palate 21 (3.4) 13 (61.9) 2 (9.5) 1 (4.8) 5 (23.8)
#
 
Abdominal wall defects 47 (7.7) 19 (40.4) 9 (19.1) 11 (23.4) 8 (17.0) 
 Gastroschisis 37 (6.1) 15 (40.5) 7 (18.9) 8 (21.6) 7 (18.9) 
 Omphalocele 9 (1.5) 3 (33.3) 2 (22.2) 3 (33.3) 1 (11.1) 
Urinary 61 (10.0) 21 (34.4) 12 (19.7) 10 (16.4) 18 (29.5) 
 Bilateral renal agenesis 0 - - - - 
 Renal dysplasia 13 (2.1) 2 (15.4) 6 (46.2) 3 (23.1) 2 (15.4)
#
 
Anomaly group All stillbirth 
 
 




(n, % of group) 
Very preterm 
 
28 - <32 wks 
(n, % of group) 
Moderate-late 
 preterm  
32 - <37 wks 




(n, % of group) 
 Congenital hydronephrosis 11 (1.8) 5 (45.5) 0 2 (18.2) 4 (36.4) 
Genital 2 (0.3) 0 0 1 (50.0) 1 (50.0) 
 Hypospadias 1 (0.2) 0 0 0 1 (100.0) 
Limb defects 41 (6.7) 26 (63.4) 4 (9.8) 6 (14.6) 5 (12.2)
#
 
 Limb reduction 9 (1.5) 4 (44.4) 2 (22.2) 1 (11.1) 2 (22.2) 
 Clubfoot/talipes equinovarus 22 (3.6) 15 (68.2) 1 (4.5) 4 (18.2) 2 (9.1)
#
 
 Hip dislocation/dysplasia 0 - - - - 
 Polydactyly 5 (0.8) 2 (40.0) 2 (40.0) 0 1 (20.0) 
 Syndactyly 1 (0.2) 1 (100.0) 0 0 0 
Other anomalies 34 (5.6) 21 (61.8) 4 (11.8) 5 (14.7) 4 (11.8)
#
 
ASD: atrial septal defect; VSD: ventricular septal defect; CHD: congenital heart disease; CNS: central nervous system 
* 




 P≤0.001 for comparison to overall mortality in all other CA. 
  
Table 4. Early and late neonatal mortality by gestational age for chromosomal anomalies, syndromes, and isolated anomalies 
 Early neonatal mortality   Late neonatal mortality 
Anomaly group All early 
neonatal 
mortality 

















(n, % of group) 
  All late 
neonatal 
mortality 

















(n, % of group) 
All anomalies 1990 (100) 174 (8.7) 297 (14.9) 630 (31.7) 889 (44.7)   703 (100) 31 (4.4) 63 (9.0) 151 (21.5) 458 (65.1) 
Chromosomal anomalies 345 (17.3) 28 (8.1) 59 (17.1) 117 (33.9) 141 (40.9)  130 (18.5) 2 (1.5) 12 (9.2) 38 (29.2) 78 (60.0) 
 Trisomy 21 50 (2.5) 7 (14.0) 3 (6.0) 17 (34.0) 23 (46.0)  26 (3.7) 1 (3.8) 3 (11.5) 10 (38.5) 12 (46.2) 
 Trisomy 18 147 (7.4) 4 (2.7) 26 (17.7) 53 (36.1) 64(43.5)
#
  48 (6.8) 1 (2.1) 2 (4.2) 14 (29.2) 31 (64.6) 
 Trisomy 13 84 (4.2) 5 (6.0) 14 (16.7) 26 (31.0) 39 (46.4)  28 (4.0) 0 4 (14.3) 5 (17.9) 19 (67.9) 
 Other 64 (3.2) 12 (18.8) 16 (25.0) 21 (32.8) 15 (23.4)
###
  28 (4.0) 0 3 (10.7) 9 (32.1) 16 (57.1) 
Syndromes 931 (46.7) 78 (8.4) 139 (14.9) 356 (38.2) 358 (38.5)  301 (42.) 8 (2.7) 34 (11.3) 72 (23.9) 187 (62.1)
##
 
 Genetic syndromes/ 
microdeletions 
67 (3.4) 8 (9.5) 9 (13.4) 23 (34.3) 27 (40.3)
###
  42 (6.0) 0 6 (12.2) 15 (30.6) 28 (57.1) 
 Monogenic anomalies 25 (1.3) 2 (8.0) 1 (4.0) 9 (36.0) 13 (52.0)  7 (1.0) 0 1 (14.3) 2 (28.6) 4 (57.1) 
 Sequences 111 (5.6) 9 (8.1) 16 (14.4) 54 (48.6) 32 (28.8)  5 (0.7) 1 (20.0) 0 2 (40.0) 2 (40.0) 
 Teratogenic anomalies 6 (0.3) 1 (16.7) 2 (33.3) 1 (16.7) 2 (33.3)  6 (0.9) 0 0 4 (66.7) 2 (33.3) 
 Skeletal dysplasias 46 (2.3) 2 (4.3) 9 (19.6) 24 (52.2) 11 (23.9)  1-4 0 0 1 (33.3) 2 (66.7) 
 Other 676 (34.0) 56 (8.3) 102 (15.1) 245 (36.2) 273 (40.4)  231 (32.9) 7 (3.0) 27 (11.7) 48 (20.8) 149 (64.5) 
Isolated anomalies 714 (35.9) 68 (9.5) 99 (13.9) 157 (22.0) 390 (54.6)  272 (38.7) 21 (7.7) 17 (6.3) 41 (15.1) 193 (71.0) 
CNS 172 (24.1) 13 (7.6) 29 (16.9) 55 (32.0) 75 (43.6)
##
  32 (11.8) 0 3 (9.4) 7 (21.9) 22 (68.8) 
 Early neonatal mortality   Late neonatal mortality 
 Neural tube defects 132 (18.5) 6 (4.5) 16 (12.1) 42 (31.8) 68 (51.5)
#
  12 (4.4) 0 1 (8.3) 1 (8.3) 10 (83.3) 
  Spina bifida 15 (2.1) 1 (6.7) 0 5 (33.3) 9 (60.0)  6 (2.2) 0 1 (16.7) 1 (16.7) 4 (66.6) 
  Anencephaly 112 (15.7) 5 (4.5) 16 (14.3) 36 (32.1) 55 (49.1)
#
  4 (1.5) 0 0 0 4 (100.0) 
  Encephalocele 5 (0.7) 0 0 1 (20.0) 4 (80.0)  2 (0.7) 0 0 0 2 (100.0) 
 Hydrocephaly 16 (2.2) 5 (31.3) 6 (37.5) 5 (31.3) 0
###
  5 (1.8) 0 1 (20.0) 1 (20.0) 3 (60.0) 
 Arhinencephaly/ 
holoprosencephaly 
8 (1.1) 1 (12.5) 1 (12.5) 4 (50.0) 2 (25.0)  2 (0.7) 0 0 1 (50.0) 1 (50.0) 
Eye anomalies 2 (0.3) 1 (50.0) 0 0 1 (50.0)  1 (0.4) 1 (100.0) 0 0 0
#
 
 Congenital cataract 0 - - - -  0 - - - - 
Ear, face, neck 1 (0.1) 0 0 1 (100.0) 0  0 - - - - 
 Anotia 1 (0.1) 0 0 1 (100.0) 0  0 - - - - 
Congenital heart defects 231 (32.4) 9 (3.9) 19 (8.2) 27 (11.7) 176 (76.2)
###
  165 (60.7) 6 (3.6) 9 (5.5) 12 (7.3) 138 (83.6)
###
 
 Severe CHD** 166 (23.2) 4 (2.4) 9 (5.4) 16 (9.6) 137 (82.5)
###
  129 (47.4) 2 (1.6) 2 (1.6) 10 (7.8) 115 (89.1)
###
 
  Transposition great 
vessels 
32 (4.5) 0 1 (3.1) 1 (3.1) 30 (93.8)
###
  24 (8.8) 0 0 3 (12.5) 21 (87.5) 
  Coarctation aorta 6 (0.8) 0 1 (16.7) 1 (16.7) 4 (66.6)  10 (3.7) 0 0 1 (10.0) 9 (90.0) 
  Fallot’s tetralogy 8 (1.1) 1 (12.5) 2 (25.0) 0  5 (62.5)  2 (0.7) 0 0 0 2 (100.0) 
  Hypoplastic left/right 
heart 
92 (12.8) 3 (3.3) 2 (2.2) 11 (12.0) 76 (82.5)
###
  62 (22.7) 1 (1.6) 0 3 (4.8) 58 (93.5)
###
 
  Single ventricle 7 (1.0) 0 0 1 (14.3) 6 (85.7)  1 (0.4) 0 0 0 1 (100.0) 
  Common arterial 
truncus 
8 (1.1) 0 1 (12.5) 2 (25.0) 5 (62.5)  9 (3.3) 0 2 (22.2) 1 (11.1) 6 (66.7) 
  Atrioventricular septal 
defect 
2 (0.3) 0 0 0 2 (100.0)  8 (2.9) 1 (12.5) 0 2 (25.0) 5 (62.5) 
 Early neonatal mortality   Late neonatal mortality 
  Tricuspid 
atresia/stenosis 
1 (0.1) 0 0 0 1 (100.0)  2 (0.7) 0 0 0 2 (100.0) 
  Ebstein’s anomaly 0 - - - -  5 (1.8) 0 0 0 5 (100.0) 
  Aortic valve 
atresia/stenosis 
5 (0.7) 0 2 (40.0) 0 3 (60.0)  2 (0.7) 0 0 1 (50.0) 1 (50.0) 
  Pulmonary valve 
atresia 
1 (0.1) 0 0 0 1 (100.0)  4 (1.5) 0 0 0 4 (100.0) 
  Total anomalous 
pulmonary venous 
return 
6 (0.8) 0 0 0 6 (100.0)  7 (2.6) 0 0 0 7 (100.0) 
 VSD (no severe CHD) 15 (2.1) 0 4 (26.7) 4 (26.7) 7 (46.6)  11 (4.0) 1 (9.1) 2 (18.2) 2 (18.2) 6 (54.5) 
 ASD (no severe CHD) 4 (0.6) 2 (50.0) 0 1 (25.0) 1 (25.0)  6 (2.2) 2 (33.3) 0 0 4 (66.7) 
 VSD+ASD (no severe CHD) 1 (0.1) 0 0 0 1 (100.0)  1 (0.4) 0 0 0 1 (100.0) 
 Pulmonary valve stenosis 
(no severe CHD) 
0 - - - -  0 - - - - 
Respiratory 51 (7.1) 11 (21.6) 14 (27.5) 12 (23.5) 14 (27.5)
###
  6 (2.2) 2 (33.3) 0 0 4 (66.7) 
 Choanal atresia 0 - - - -  0 - - - - 
Digestive 128 (17.9) 4 (3.1) 20 (15.6) 25 (19.5) 79 (61.7)
#
  35 (12.9) 4 (11.4) 1 (2.9) 12 (34.3) 18 (51.4)
#
 
 Diaphragmatic hernia 97 (13.6) 0 11 (11.3) 19 (19.6) 67 (69.1)
##
  11 (4.0) 0 0 2 (18.2) 9 (81.8) 
Orofacial clefts 16 (2.2) 7 (43.8) 3 (18.8) 3 (18.8) 3 (18.8)
###
  0 - - - - 
 Cleft lip with/without cleft 
palate 
10 (1.4) 5 (50.0) 1 (10.0) 2 (20.0) 2 (20.0)
###
  0 - - - - 
Abdominal wall defects 23 (3.2) 4 (17.4) 4 (17.4) 9 (39.1) 6 (26.1)
#
  11 (4.0) 0 1 (9.1) 6 (54.5) 4 (36.4)
#
 
 Gastroschisis 12 (1.7) 1 (8.3) 3 (25.0) 4 (33.3) 4 (33.3)  10 (3.7) 0 1 (10.0) 5 (50.0) 4 (40.0)
#
 
 Omphalocele 9 (1.3) 3 (33.3) 1 (11.1) 3 (33.3) 2 (22.2)  1 (0.4) 0 0 1 (100.0) 0 
 Early neonatal mortality   Late neonatal mortality 
Urinary 60 (8.4) 4 (6.7) 8 (13.3) 26 (43.3) 22 (36.7)
###
  14 (5.1) 4 (28.6) 3 (21.4) 2 (14.3) 5 (35.7)
##
 
 Bilateral renal agenesis 1 (0.1) 0 0 1 (100.0) 0  0 - - - - 
 Renal dysplasia 16 (2.2) 1 (6.3) 3 (18.8) 8 (50.0) 4 (25.0)
#
  4 (1.5) 2 (50.0) 1 (25.0) 0 1 (25.0)
#
 
 Congenital hydronephrosis 10 (1.4) 2 (20.0) 0 5 (50.0) 3 (30.0)  0 - - - - 
Genital 8 (1.1) 2 (25.0) 2 (25.0) 3 (37.5) 1 (12.5)  0 - - - - 
 Hypospadias 2 (0.3) 0 1 (50.0) 1 (50.0) 0  0 - - - - 
Limb defects 20 (2.8) 10 (50.0) 3 (15.0) 3 (15.0) 4 (20.0)
##
  5 (1.8) 3 (60.0) 1 (20.0) 1 (20.0) 0
 ###
 
 Limb reduction 5 (0.7) 3 (60.0) 0 0 2 (40.0)
#
  0 - - - - 
 Clubfoot/talipes 
equinovarus 
7 (1.0) 4 (57.1) 2 (28.6) 0 1 (14.3)
###
  3 (1.1) 2 (66.7) 0 1 (33.3) 0
 ##
 
 Hip dislocation/dysplasia 0 - - - -  1 (0.4) 1 (100.0) 0 0 0
 #
 
 Polydactyly 4 (0.6) 2 (50.0) 1 (25.0) 0 1 (25.0)
#
  1 (0.4) 0 1 (100.0) 0 0
 #
 
 Syndactyly 1 (0.1) 0 0 1 (100.0) 0  0 - - - - 
Other malformations 29 (4.1) 4 (13.8) 3 (10.3) 5 (17.2) 17 (58.6)  6 (2.2) 1 (16.7) 0 1 (16.7) 4 (66.6) 
 
ASD: atrial septal defect; VSD: ventricular septal defect; CHD: congenital heart disease; CNS: central nervous system 




 P ≤ 0.001, 
###
 P<0.0005 
